In the BioHarmony Drug Report Database
Tepotinib
Tepmetko (tepotinib) is a small molecule pharmaceutical. Tepotinib was first approved as Tepmetko on 2021-02-03. The pharmaceutical is active against hepatocyte growth factor receptor. Tepmetko’s patents are valid until 2030-03-19 (FDA).
Trade Name
|
Tepmetko |
|---|---|
Common Name
|
tepotinib |
ChEMBL ID
|
CHEMBL3402762 |
Indication
|
|
Drug Class
|
Tyrosine kinase inhibitors |
Image (chem structure or protein)